Floatz logo

Bms-214662

Recurrent Childhood Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Recurrent Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Bms-214662 is also rated in:

cancer of unknown primary siteDormant
B
Indicative ·
58 / 100
View asset →
childhood neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →